Vishal Mega Mart, Sai Life Sciences: Shares Worth Rs 39,000 Crore To Exit Lock-Ins On Tuesday
As many as 254.2 crore shares of Vishal Mega Mart worth Rs 31,775 crore will become free to trade.

Shares worth over Rs 39,385 crore of Vishal Mega Mart Ltd. and Sai Life Sciences Ltd. are set to exit their respective lock-in periods on Tuesday.
As much as 56% equity of Vishal Mega Mart and 48% equity of Sai Life Sciences is set to become eligible for trade as the six-month lock-in period ends for shareholders, as per Nuvama's report.
As many as 254.2 crore shares of Vishal Mega Mart worth Rs 31,775 crore will become free to trade.
The shareholding valued at Rs 31,775 crore, is nearly four times more than the IPO issue size of Rs 8,000 crore. Currently, the company has Rs 14,131 crore in free float market capitalisation for public to trade.
As much as 48% of the equity or 10 crore shares worth Rs 7,610 crore will become free to trade for Sai Life Sciences.
Sai life Sciences' shareholding valued at Rs 7,610 crore is 2.5 times more than the IPO issue size. Currently, Rs 4,900 crore free float market capitalisation is available for public to trade.
How Share Prices Have Moved
Vishal Mega Mart made a strong debut on the bourses, listing at Rs 104 against its IPO price of Rs 78. The stock surged to an all-time high of Rs 135 before settling around Rs 125 currently, down about 7.5% from its peak but still delivering an impressive 60% return over the IPO price. The performance reflects strong investor interest and confidence in stock.
Sai Life Sciences has delivered a robust post-IPO performance, listing at Rs 764 compared to its IPO price of Rs 549. The stock reached an all-time high of Rs 808 and is currently trading at Rs 763, just 5.56% below its all-time high. Despite a slight pullback, it remains 38% above its issue price, reflecting strong investor confidence in the company’s position.
Analysts' View
Out of nine analysts tracking Vishal Mega Mart, seven recommend a 'Buy', one recommends a 'Hold', and one 'Sell'. Morgan Stanley has the most bullish target at Rs 161, while Bernstein has a bearish view with a Rs 90 target.
Meanwhile, Sai Life Sciences is being tracked by four analysts, with two with a 'Buy' ,one 'Hold', and one ‘Sell' rating. Morgan Stanley again leads to the upside with a target price of Rs 911.